ReleaseWire

Global Markets Direct's, 'Catalyst Biosciences, Inc. - Product Pipeline Review - 2014', provides an overview of the Catalyst Biosciences, Inc.'s pharmaceutical research and development focus.

GlobalData has released its new PharmaPoint Drug Evaluation report, "MGN1703 (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Actinium Pharmaceuticals, Inc, a New York City-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a CMC (Chemistry, Manufacturing and Control) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently undergoing preparations for starting the pivotal Phase 3 trial by the middle of 2015. The Company expects to obtain further guidance from the FDA that will allow completion of the processes and methods for large scale manufacturing and testing of clinical and commercial grade drug product.

Advanced Accelerator Applications S.A. ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), announced that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada and focused on the development of proprietary molecular imaging products aimed at imaging apoptosis and necrosis based on Annexin V. Atreus Pharmaceuticals Corporation is now a fully owned AAA subsidiary and has been renamed AAA Canada.

Global Markets Direct's, 'Ambryx Biotechnology, Inc. - Product Pipeline Review - 2014', provides an overview of the Ambryx Biotechnology, Inc.'s pharmaceutical research and development focus.

St. Louis Pharmacy technician schools are offering certified degrees through Midwest Institute with an aim to help those who want to take up the career of a pharmacy technician. The career of a pharmacy technician has been witnessing an upward trend and there is a very good demand for this career.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Stivarga (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Global Markets Direct's, 'Tesaro, Inc. - Product Pipeline Review - 2014', provides an overview of the Tesaro, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Valens Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Valens Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Novogen Limited - Product Pipeline Review - 2014', provides an overview of the Novogen Limited's pharmaceutical research and development focus.

GlobalData's clinical trial report, "Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2014" provides data on the Hospital Acquired Pneumonia (HAP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hospital Acquired Pneumonia (HAP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hospital Acquired Pneumonia (HAP). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'PCI Biotech AS - Product Pipeline Review - 2014', provides an overview of the PCI Biotech AS's pharmaceutical research and development focus.

Global Markets Direct's, 'Primary Biliary Cirrhosis - Pipeline Review, H2 2014', provides an overview of the Primary Biliary Cirrhosis's therapeutic pipeline.

Global Markets Direct's, 'Osmotica Pharmaceutical Corp. - Product Pipeline Review - 2014', provides an overview of the Osmotica Pharmaceutical Corp.'s pharmaceutical research and development focus.

Global Markets Direct's, 'ELORAC, Inc. - Product Pipeline Review - 2014', provides an overview of the ELORAC, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'FORUM Pharmaceuticals Inc. - Product Pipeline Review - 2014', provides an overview of the FORUM Pharmaceuticals Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'NovoBiotic Pharmaceuticals, LLC - Product Pipeline Review - 2014', provides an overview of the NovoBiotic Pharmaceuticals, LLC's pharmaceutical research and development focus.

Global Markets Direct's, 'Traveler's Diarrhea - Pipeline Review, H2 2014', provides an overview of the Traveler's Diarrhea's therapeutic pipeline.

Global Markets Direct's, 'Edison Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Edison Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Adamed Sp. z o.o. - Product Pipeline Review - 2014', provides an overview of the Adamed Sp. z o.o.'s pharmaceutical research and development focus.

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

GlobalData's clinical trial report, "HIV-2 Infection Global Clinical Trials Review, H2, 2014" provides data on the HIV-2 Infection clinical trial scenario. This report provides elemental information and data relating to the clinical trials on HIV-2 Infection. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating HIV-2 Infection. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Taisho Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Vanda Pharmaceuticals Inc. - Product Pipeline Review - 2014', provides an overview of the Vanda Pharmaceuticals Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Seikagaku Corporation - Product Pipeline Review - 2014', provides an overview of the Seikagaku Corporation's pharmaceutical research and development focus.